Login to Your Account



Ultragenyx gearing up for BLA after positive phase III XLH study

By Jennifer Boggs
Managing Editor

Wednesday, April 19, 2017

Ultragenyx Pharmaceutical Inc. said it believes data from a phase III study testing burosumab, a recombinant fully human monoclonal IgG1 antibody, are sufficient to support a BLA filing this year in X-linked hypophosphatemia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription